Catalent to manufacture Moderna's personalized cancer vaccine for Ph I/II studies

By Melissa Fassbender contact

- Last updated on GMT

Clinical study of Moderna's mRNA personalized cancer vaccine is expected to begin in 2017. (Image: Catalent)
Clinical study of Moderna's mRNA personalized cancer vaccine is expected to begin in 2017. (Image: Catalent)

Related tags: Vaccine

Catalent has entered into an agreement with Moderna Therapeutics to support the company’s proprietary production process.

Mike Riley, VP and General Manager of Catalent​ Biologics confirmed that the company will be providing cGMP manufacturing of Moderna’s mRNA personalized cancer vaccine for phase I/II clinical studies.

According to the company, clinical study of the vaccine is expected to begin in 2017.

Under the agreement, Catalent will be providing dedicated production capability to accommodate Moderna’s proprietary production process, and support fast turnaround of clinical material​,” Riley told us.

Work will take place at Catalent’s Madison, WI-based facility, which was opened in 2013 to support both flexible cGMP and non-GMP production.

The site features integrated process development and analytical capabilities, including the support of method development, in-process, release and stability testing​,” said Riley.

Additionally, Catalent recently announced an expansion to the facility, which Riley said will create increased capacity for later phase clinical and commercial production.

Related topics: Bio-Outsourcing

Related news

Show more

Related products

show more

High-Density Vero Cell Perfusion Culture

High-Density Vero Cell Perfusion Culture

Eppendorf for Bioprocess – Solutions that grow with you | 01-May-2018 | Application Note

Viral diseases like rabies, rotavirus and influenza are causing many deaths worldwide, resulting in a strong demand for more productive manufacturing techniques...

Related suppliers

Follow us

Products

View more

Webinars